Peptone partners with Evotec

I’m thrilled to share some exciting news about a game-changing partnership between Peptone, where I serve as CEO, and Evotec, a powerhouse in drug discovery. We announced this collaboration on May 8, 2025, and it’s a big step forward in our mission to tackle intrinsically disordered proteins (IDPs)—those tricky, shape-shifting molecules that have long been considered “undruggable” but hold immense potential for treating diseases.

Working with Evotec feels like joining forces with a kindred spirit in innovation. Their expertise in oncology, immunology, and cutting-edge screening tech perfectly complements our physics-based approach at Peptone. We’re using our proprietary Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) platform to decode the structural dynamics of IDPs, and Evotec’s robust medicinal chemistry libraries and assay know-how are helping us turn those insights into real therapeutic solutions. Together, we’re zeroing in on high-value targets like transcription factors and kinases, which could unlock new treatments across a range of diseases.

What excites me most is how this partnership accelerates our work. Evotec’s tools and experience are supercharging our ability to select and validate IDP targets, bringing us closer to delivering therapies that could make a real difference for patients. It’s a privilege to collaborate with a team so committed to pushing the boundaries of what’s possible in drug discovery.